A B C Dy1,2,3, F Tassone3,4, M Eldeeb3,5, M J Salcedo-Arellano3,5, N Tartaglia6, R Hagerman3,5. 1. Ateneo de Manila University School of Medicine and Public Health, Pasig City, Philippines. 2. MedMom Institute for Human Development, Pasig City, Philippines. 3. Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California, Davis Medical Center, Sacramento, California. 4. Department of Biochemistry and Molecular Medicine, University of California Davis Medical Center, Sacramento, California. 5. Department of Pediatrics, University of California Davis Medical Center, Sacramento, California. 6. Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado.
Abstract
BACKGROUND: Individuals with fragile X syndrome (FXS) have both behavioral and medical comorbidities and the latter include obesity in approximately 30% and the Prader-Willi Phenotype (PWP) characterized by severe hyperphagia and morbid obesity in less than 10%. Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults. Recently published studies in the Drosophila model and the knock out mouse model of FXS treated with metformin demonstrate the rescue of multiple phenotypes of FXS. MATERIALS AND METHODS: We present 7 cases of individuals with FXS who have been treated with metformin clinically. One case with type 2 diabetes, 3 cases with the PWP, 2 adults with obesity and/or behavioral problems and, a young child with FXS. These individuals were clinically treated with metformin and monitored for behavioral changes with the Aberrant Behavior Checklist and metabolic changes with a fasting glucose and HgbA1c. RESULTS: We found consistent improvements in irritability, social responsiveness, hyperactivity, and social avoidance, in addition to comments from the family regarding improvements in language and conversational skills. No significant side-effects were noted and most patients with obesity lost weight. CONCLUSION: We recommend a controlled trial of metformin in those with FXS. Metformin appears to be an effective treatment of obesity including those with the PWP in FXS. Our study suggests that metformin may also be a targeted treatment for improving behavior and language in children and adults with FXS.
BACKGROUND: Individuals with fragile X syndrome (FXS) have both behavioral and medical comorbidities and the latter include obesity in approximately 30% and the Prader-Willi Phenotype (PWP) characterized by severe hyperphagia and morbid obesity in less than 10%. Metformin is a drug used in individuals with type 2 diabetes, obesity or impaired glucose tolerance and it has a strong safety profile in children and adults. Recently published studies in the Drosophila model and the knock out mouse model of FXS treated with metformin demonstrate the rescue of multiple phenotypes of FXS. MATERIALS AND METHODS: We present 7 cases of individuals with FXS who have been treated with metformin clinically. One case with type 2 diabetes, 3 cases with the PWP, 2 adults with obesity and/or behavioral problems and, a young child with FXS. These individuals were clinically treated with metformin and monitored for behavioral changes with the Aberrant Behavior Checklist and metabolic changes with a fasting glucose and HgbA1c. RESULTS: We found consistent improvements in irritability, social responsiveness, hyperactivity, and social avoidance, in addition to comments from the family regarding improvements in language and conversational skills. No significant side-effects were noted and most patients with obesity lost weight. CONCLUSION: We recommend a controlled trial of metformin in those with FXS. Metformin appears to be an effective treatment of obesity including those with the PWP in FXS. Our study suggests that metformin may also be a targeted treatment for improving behavior and language in children and adults with FXS.
Authors: P Tounian; M L Frelut; G Parlier; C Abounaufal; N Aymard; F Veinberg; J L Fontaine; J P Girardet Journal: Int J Obes Relat Metab Disord Date: 1999-08
Authors: C A Bannister; S E Holden; S Jenkins-Jones; C Ll Morgan; J P Halcox; G Schernthaner; J Mukherjee; C J Currie Journal: Diabetes Obes Metab Date: 2014-07-31 Impact factor: 6.577
Authors: Evdokia Anagnostou; Michael G Aman; Benjamin L Handen; Kevin B Sanders; Amy Shui; Jill A Hollway; Jessica Brian; L Eugene Arnold; Lucia Capano; Jessica A Hellings; Eric Butter; Deepali Mankad; Rameshwari Tumuluru; Jessica Kettel; Cassandra R Newsom; Stasia Hadjiyannakis; Naomi Peleg; Dina Odrobina; Sarah McAuliffe-Bellin; Pearl Zakroysky; Sarah Marler; Alexis Wagner; Taylor Wong; Eric A Macklin; Jeremy Veenstra-VanderWeele Journal: JAMA Psychiatry Date: 2016-09-01 Impact factor: 21.596
Authors: Randi J Hagerman; Elizabeth Berry-Kravis; Walter E Kaufmann; Michele Y Ono; Nicole Tartaglia; Ave Lachiewicz; Rebecca Kronk; Carol Delahunty; David Hessl; Jeannie Visootsak; Jonathan Picker; Louise Gane; Michael Tranfaglia Journal: Pediatrics Date: 2009-01 Impact factor: 7.124
Authors: Michael Bodmer; Christian Meier; Stephan Krähenbühl; Susan S Jick; Christoph R Meier Journal: Diabetes Care Date: 2008-09-09 Impact factor: 17.152
Authors: Ramy Ayoub; Rebecca M Ruddy; Elizabeth Cox; Adeoye Oyefiade; Daniel Derkach; Suzanne Laughlin; Benjamin Ades-Aron; Zahra Shirzadi; Els Fieremans; Bradley J MacIntosh; Cynthia B de Medeiros; Jovanka Skocic; Eric Bouffet; Freda D Miller; Cindi M Morshead; Donald J Mabbott Journal: Nat Med Date: 2020-07-27 Impact factor: 53.440
Authors: Dong Liu; Carmen Nanclares; Konstanze Simbriger; Kun Fang; Ethan Lorsung; Nam Le; Inês Silva Amorim; Kleanthi Chalkiadaki; Salil Saurav Pathak; Jin Li; Jonathan C Gewirtz; Victor X Jin; Paulo Kofuji; Alfonso Araque; Harry T Orr; Christos G Gkogkas; Ruifeng Cao Journal: Mol Psychiatry Date: 2022-03-17 Impact factor: 13.437
Authors: Ai Zhang; Irina Sokolova; Alain Domissy; Joshua Davis; Lee Rao; Kagistia Hana Utami; Yanling Wang; Randi J Hagerman; Mahmoud A Pouladi; Pietro Sanna; Michael J Boland; Jeanne F Loring Journal: Stem Cells Transl Med Date: 2022-06-22 Impact factor: 7.655
Authors: Maria Jimena Salcedo-Arellano; Ana Maria Cabal-Herrera; Ruchi Harendra Punatar; Courtney Jessica Clark; Christopher Allen Romney; Randi J Hagerman Journal: Neurotherapeutics Date: 2020-11-19 Impact factor: 7.620
Authors: Li Dai; Robert B Weiss; Diane M Dunn; Anna Ramirez; Sharan Paul; Julie R Korenberg Journal: Hum Mol Genet Date: 2021-04-30 Impact factor: 6.150